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Abstract
The neural factors underlying individual differences in susceptibility to chronic stress remain
poorly understood. Preclinical studies demonstrate that mouse strains vary greatly in anxiety-
related responses to chronic stress in a manner paralleled by differential stress-induced changes in
glutamatergic signaling in the basolateral amygdala (BLA). Previous work has also shown that
alterations in the amygdala gene expression of the GluN1 NMDA and the GluK1 kainate receptors
are associated with stress-induced alterations in anxiety-like behavior in the C57BL/6J mouse
strain. Using in vivo behavioral pharmacological and ex vivo physiological approaches, the aim of
the current study was to further elucidate changes in glutamate neurotransmission in the BLA
caused by stress and to test the functional roles of GluN1 and GluK1 in mediating stress-related
changes in behavior. Results showed that stress-induced alterations in anxiety-like behavior (light/
dark exploration test) were absent following bilateral infusion of the GluK1 agonist ATPA into the
BLA. Intra-BLA infusion of the competitive NMDA antagonist AP5 produced a generalized
behavioral disinhibition/locomotor hyperactivity, irrespective of stress. Slice electrophysiological
recordings showed that ATPA augmented BLA GABAergic neurotransmission and that stress
increased the amplitude of network-dependent spontaneous excitatory postsynaptic currents and
amplitude of GABAergic miniature inhibitory postsynaptic currents in BLA. These findings could
indicate stress-induced BLA glutamatergic neuronal network hyperexcitability and a
compensatory increase in GABAergic neurotransmission, suggesting that GluK1 agonism
augmented GABAergic inhibition to prevent behavioral sequelae of stress. Current data could
have implications for developing novel therapeutic approaches, including GluK1 agonists, for
stress-related anxiety disorders.
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Psychological stress is a major risk factor for various neuropsychiatric conditions and
individuals differ in their sensitivity to stress, partly due to predisposing genetic and
neurobiological factors (Caspi et al., 2010). Rodent models offer an experimentally tractable
strategy for studying the effects of stress on behavior, and then delineating the mediating
neural factors (Holmes and Singewald, 2013). We have previously found that following
stress C57BL/6J mice showed a pattern ostensibly indicative of decreased anxiety-like
behavior (i.e., more time in the light compartment of the light/dark exploration test and open
arms of the elevated plus-maze). However, further analysis suggests that this stress-induced
response in C57BL/6J mice can be interpreted as an anxiety-related drive to escape the
apparatus or an ‘active-coping’ response (Mozhui et al., 2010; Uchida et al., 2011) – a
hypothesis supported by the finding that the response was effectively reversed by chronic
treatment with the anxiolytic fluoxetine (Ihne et al., 2012).
The neural and molecular basis of these stress-induced behavioral abnormalities currently
remains unclear. The basolateral amygdala (BLA) is activated by stressors (Singewald,
2007; Whittle et al., 2010) and is a major target of chronic stress (Duvarci and Pare, 2007;
Kavushansky and Richter-Levin, 2006; Maroun et al., 2013; Reznikov et al., 2009;
Roozendaal et al., 2009). Gene expression analysis of multiple corticolimbic regions,
including the BLA, from C57BL/6J before and after chronic stress exposure revealed
differential expression of multiple genes (Mozhui et al., 2010). Intriguingly, there was
increased gene expression of Grin1 (GluN1 subunit NMDA receptor) and decreased
expression of Grik1 mRNA (GluK1, formerly GluR5, kainate receptor subtype) in the BLA
of C57BL/6J mice following stress.
These prior findings are of particular interest given GluN1 and GluK1 are important
regulators of amygdala synaptic transmission and plasticity (Aroniadou-Anderjaska et al.,
2012; Lack et al., 2008; Li and Rogawski, 1998; Wu et al., 2007), and more generally, in the
context of a growing literature implicating amygdala glutamate signaling in stress-related
anxiety (Cryan and Dev, 2007; Griebel and Holmes, 2013; Krishnan et al., 2007; Surget et
al., 2009). The functional roles of amygdala GluK1 and GluN1 in mediating stress-induced
anxiety in C57BL/6J mice are unclear, as is the precise nature of the stress-induced changes
in amygdala glutamate-mediated synaptic transmission. The major aim of the current study
was to address these questions using a combination of in vivo behavioral pharmacological
and ex vivo electrophysiological approaches.
2. Material and methods
2.1. Subjects
Subjects were 2–3 month old male C57BL/6J mice obtained from The Jackson Laboratory
(Bar Harbor, ME, USA). Following shipping, mice were acclimated to the vivarium for at
least 1 week prior to experimental manipulation in a temperature-(22 ± 3 °C) and humidity-
(45 ± 15%) controlled vivarium under a 12-h light/dark cycle (lights on at 06:00). Food and
water were provided ad libitum. Separate cohorts of mice were used for the behavioral and
electrophysiological experiments. All experimental procedures were approved by the
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NIAAA and UNC Animal Care and Use Committees, and followed the National Institutes of
Health guidelines outlined in “Using Animals in Intramural Research.”
2.2. Implantation of amygdala-targeting guide cannula
Mice were anesthetized with isoflurane and bilaterally implanted via stereotaxic surgery
(Kopf Instruments, Tujunga, CA, USA) with 26-gauge indwelling cannulae (Plastics One,
Roanoke, VA, USA) targeting the BLA, as previously described (Gunduz-Cinar et al.,
2013). The coordinates were AP −1.4, ML ±3.3, DV −3.8 to −4.1. Mice were single-housed
following surgery and given a 1-week recovery period before stress during which dummy
cannulae were intermittently manipulated to habituate mice to handling and prevent cannula
blocking.
To verify cannula placements at the completion of testing (see Fig. 1B), mice were perfused
with 4% paraformaldehyde. Fixed brains were sectioned (50 μm thickness) on a vibrating
microtome (American Optical 860, San Marcos, USA) and stained with cresyl violet to aid
localization of cannula tips. Cases in which cannula were not bilaterally localized in the
BLA were excluded. To further confirm the localization of infusion, some mice were
infused with a fluorophore (BODIPY® TMR-X, SE, 5 mM in PBS, DMSO 40%, Invitrogen,
Eugene, OR, USA) and brain (50 μm-thick) sections visualized with a SteREO Lumar V12,
Fluorescent Microscope (Carl Zeiss Microscopy LLC, Thornwood, USA) equipped with a
CY3 filter (545/25 nm excitation, 565 lpxr dichroic, and 605/70 nm emission) (see Fig. 1C).
2.3. Repeated restraint stress
Mice were placed in ventilated 50 mL Falcon tubes for 2 h per day (10:00– 12:00 h) for 10
consecutive days, while non-restrained mice remained in their home cage, as previously
described (Ihne et al., 2012; Mozhui et al., 2010). Body weight was measured before and
after the 10-day stress period to confirm that stress led to a loss of body weight (Ihne et al.,
2012; Mozhui et al., 2010).
2.4. Drug infusion and behavioral testing
One day after the final stress exposure, mice were tested on the light/dark exploration test
(LDE) for anxiety-related behavior (Crawley, 1981; Yang et al., 2008) (for schematic of
experimental design, see Fig. 1A). The apparatus and procedure was as previously described
(Ihne et al., 2012; Mozhui et al., 2010). The apparatus was an opaque black Plexiglas shelter
(39 × 13 × 16 cm) with a 13 × 8 cm aperture at floor level that opened onto a large white
Plexiglas square arena (39 × 39 × 35 cm) illuminated to ~90 lux. Mice were placed halfway,
head-forward, in the shelter to begin a 15-min session. The latency to first exit the shelter
and enter the light compartment, the number of entries into the light compartment, the
accumulated time spent in the light compartment, and the accumulated distance traveled in
the light and dark compartments during the first 5 min of the session was measured by the
Ethovision videotracking system (Noldus Information Technology Inc., Leesburg, VA,
USA).
Mice were randomly assigned to 1 of 3 drug groups: 2.5 μg AP5 sodium salt (NMDAR
antagonist), 125 pmol ATPA (GluK1 agonist), or 0.9% saline vehicle. Drug concentrations
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were chosen based on previous studies in rats or mice (Holmes et al., 2012; Lack et al.,
2008; Walker et al., 2002). Fifteen minutes prior to testing, bilateral 33-gauge injectors
(Plastics One, Roanoke, VA, USA) with 1 mm projection were lowered into the indwelling
guide cannulae. A volume of 0.3 μl per hemisphere was infused via a syringe pump
(Harvard Apparatus PHD 22/2000, Holliston, MA, USA) at a rate of 0.25 μl per minute. To
ensure diffusion into the brain and minimize reflux, custom-modified injector needles with a
1.2–1.3 mm projection beyond the cannula tip were inserted prior to infusion to produce a
small space in the tissue, and injectors were left in place for 5 min to allow for complete
diffusion and then removed. Mice remained in the homecage until testing.
2.5. Slice electrophysiology
One day following the final exposure to stress, mice were sacrificed via deep isoflurane
anesthesia and decapitation, and brain slices containing the BLA were prepared as
previously described (Li et al., 2012; Mozhui et al., 2010). Briefly, following sacrifice,
brains were rapidly removed and 300 μm slices were cut on a Leica VT1000S vibratome
(Leica Biosystems, Buffalo Grove, IL, USA) in a cold (1–4 °C), sucrose-based external
solution. Slices were then immediately placed in normal ACSF at 30 °C and allowed to
recover for at least 1 h. Following recovery, individual slices were placed in a holding
chamber and continuously perfused with normal ACSF maintained at 30 °C at a rate of 2
mL per minute. Neurons were visualized using infrared video microscopy (Olympus, Center
Valley, PA, USA). Recording electrodes (3–5 MΩ) were pulled with a Flaming-Brown
Micropipette Puller (Sutter Instruments, Novato, CA, USA), using thin-walled borosilicate
glass capillaries. Signals were acquired by a Multiclamp 700 B amplifier (Molecular
Devices, Sunnyvale, CA, USA), digitized at 10 kHz, and analyzed using Clampfit 10.2
software (Molecular Devices, Sunnyvale, CA, USA). Input resistance and access resistance
were continuously monitored throughout all experiments, and those in which changes in
access resistance exceeded 20% were excluded from all data analyses.
Whole-cell voltage clamp recordings were performed to test for alterations in synaptic
plasticity, as measured by AMPAR/NMDAR ratio, a putative marker for synaptic
potentiation (Humeau et al., 2007), using a cesium gluconate-based internal solution [(in
mM) 117 gluconic acid, 20 HEPES, 0.4 EGTA, 5 TEA, 2 MgCL2, 2 QX-314, 4 Na2ATP,
0.4 Na2GTP, pH 7.3, 285–290 mOsmol]. Evoked NMDAR-mediated synaptic transmission
was examined by placing a stimulating electrode in the dorsal part of the BLA and then
measuring the relationship between stimulus intensity and peak amplitude of evoked
NMDAR mediated currents. Fast synaptic transmission, which is primarily AMPAR-
mediated (Christian et al., 2013), was assessed from recording pharmacologically isolated
spontaneous synaptic events at a membrane potential of −70 mV, in the presence of
picrotoxin.
To simultaneously record both spontaneous excitatory and inhibitory events from individual
neurons, the recording configuration was altered by adjusting the intracellular solution, and
then recording at the reversal potential for the opposing current, as previously described for
other brain regions (Kim et al., 2013). Specifically, inhibitory postsynaptic currents (IPSCs)
were recorded at +10 mV, the reversal potential for AMPAR-mediated currents, and
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excitatory postsynaptic currents (EPSCs) were recorded at −55 mV, the reversal potential for
GABAR-mediated events, using a cesium methanesulfonate-based intracellular solution [(in
mM) 135 cesium methanesulfonate, 10 KCl, 1 MgCl2, 0.2 EGTA, 2 QX-314, 4 MgATP, 0.3
GTP, 20 phosphocreatine, pH 7.3, 285–290 mOsmol). To determine network-independent
synaptic transmission, recordings were repeated in the presence of the sodium channel
blocker tetrodotoxin, which blocks action potential firing and thereby recurrent network-
driven transmission.
GluK1 signaling in the BLA has been suggested to effect anxiety-like behavior by
modulating the excitability of GABAergic interneurons, based on the observation that intra-
BLA injection of the GluK1 blockade increases anxiety-like behavior while application of
the GluK1 agonist, ATPA, depolarizes interneurons and increases spontaneous GABAergic
transmission in this region (Wu et al., 2007). To test for alterations in GluK1 modulation of
BLA function, recordings were made after pharmacologically isolating GABAergic
transmission by including 50 μM APV (NMDAR antagonist) and 100 μM GYKI53655
(AMPAR antagonist) in the extracellular solution. IPSCs were recorded at +10 mV using a
cesium gluconate-based internal solution. Following the establishment of a stable baseline,
the GluK1 agonist, ATPA, was bath applied at a concentration of 3 μM for 10 min followed
by a 10 min washout period.
2.6. Statistical analysis
The effect of stress exposure and drug treatment on body weight and behavioral measures
was analyzed using 2-factor analysis of variance (ANOVA). Bonferonni-adjusted post-hoc
tests were used to probe significant ANOVA terms. As effects of stress and drug treatment
were predicted a priori, planned t-tests were conducted to compare groups in the absence of
significant ANOVA terms. Outliers were identified as cases with behavioral scores >2
standard deviations from each overall group mean, resulting in the exclusion of one case
from each of the following groups: non-stressed/vehicle, non-stressed/AP5, stressed/vehicle,
non-stressed/ATPA. For electrophysiology experiments, the effects of stress on synaptic
plasticity were assessed using t-tests (using Welch’s correction where variances were
unequal). The effects of stress on the amplitude of NMDAR currents across a range of
stimulation intensities were analyzed using 2-factor (treatment × stimulus intensity)
ANOVA, with repeated measures for stimulus intensity. The effects of stress on the
response to bath application of ATPA were normalized to baseline values and assessed as
the percent change from baseline using 2-factor (time × treatment) ANOVA, with repeated
measures for time. The threshold for statistical significance was set at P < .05.
3. Results
3.1. Effects of intra-BLA AP5 and ATPA on stress-induced LDE test behavior
There was a significant effect of stress on pre- versus post-stress body weight, due to a
significant decrease in body weight in all 3 groups of stressed mice relative to a significant
increase in non-stressed controls over the same period (effect of stress: F1,37 = 98.95, P < .
01) (Fig. 2A).
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In the LDE test, there was a significant main effect of stress on percent light time (F1,37 =
7.20, P <.05), light entries (F1,37 =4.25, P <.05) and distance traveled in the light (F1,37 =
9.00, P <.01), as well as a significant main effect of drug treatment on percent light time
(F2,37 =4.44, P <.05), light entries (F2,37 = 16.20, P <.01) and distance traveled in the light
compartment (F2,37 = 17.97, P < .01), but no significant stress × treatment interactions.
Bonferroni-adjusted post-hoc comparisons probing the main effect of drug demonstrate that
AP5 treatment significantly increased percent light time (P < .05), light entries (P < .05) and
distance traveled in the light compartment (P < .05), relative to both vehicle treatment and
ATPA treatment, irrespective of stress. Bonferonni-adjusted post-hoc comparisons probing
the main effect of stress demonstrate that stress did not significantly alter LDE behaviors in
vehicle- or ATPA-treated mice, but did significantly increase percent light time (P < .05)
and distance traveled in the light compartment (P < .05), but not entries in to the light (P > .
05), in AP5 treated mice relative to AP5 treated controls. Because previous data from our
lab has demonstrated that C57BL/6J mice spend more time in the light compartment
following a restraint stress protocol identical to the one used in the current study, we
performed planned t-test comparisons to probe the effects of drug treatment on stress-
induced LDE behavior (Mozhui et al., 2010; Uchida et al., 2011). These comparisons
showed that vehicle-treated stressed mice spent significantly more percent time in the light
(t(11) = 2.53, P <.05) and traveled farther in the light (but not dark) compartment (t(11) =
2.29, P <.05 for light; t(11) = 0.88, P >.05 for dark, data not shown), and showed a trend for
more light entries (t(11) = 2.16, P =.053), as compared to vehicle-treated non-stressed
controls (Fig. 2B–D). Thus, in agreement with previous reports, stress increased preference
for the light compartment. Notably, stress-related effects on percent time in the light were
absent in mice infused with ATPA (t(14) = 0.25, P > .05 for percent time in light; t(14) =
0.27, P >.05 for entries in light; t(14) = 0.52, P >.05 for distance traveled in light),
suggesting that activation of BLA kainite receptors attenuates the effects of stress. In mice
infused with AP5, stress-related effects were not observed in entries in light (t(12) = 1.505,
P >.05), though stress-related effects were apparent in distance traveled in the light (t(12) =
2.220, P < .05) and a non-significant trend was observed for percent time in light (t(12) =
2.006, P > .05). Thus, AP5 treatment appeared to augment the effects of stress on specific
aspects of LDE behavior. Because potential non-specific locomotor effects of the drugs
could confound the effects of stress on LDE behavior, total distance traveled during the
entire 15-min assay was analyzed (Fig. 2D inset). There were significant main effects of
stress (F1,37 = 6.594, P <.05) and drug (F2, 37 = 34.39, P <.05) on total distance traveled
for the duration of the 15-min assay. Bonferonni-adjusted post-hoc comparisons revealed the
AP5 significantly enhanced the total distance traveled as compared to both the vehicle
treatment and ATPA treatment, regardless of stress exposure (P <.05). In addition, stress
significantly enhanced total distance traveled only in AP5-treated mice (P < .05). Thus, AP5
treatment non-specifically enhanced locomotion. Further analysis with planned comparison
t-tests to probe specific drug and stress effects on locomotion demonstrates that stress did
not alter drug effects on total distance traveled (t(11) = 1.716, P > .05 for vehicle-treated
mice; t(14) = 0.2334, P >.05 for ATPA-treated mice; t(12) = 2.021, P >.05 for AP5-treated
mice), though a non-significant trend was observed in AP5-treated mice. Thus, while stress
did not alter total locomotion in vehicle- and ATPA-treated mice, it enhanced locomotion in
AP5-treated mice.
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3.2. Effects of stress on BLA synaptic transmission
There was no significant effect of stress on AMPAR/NMDAR ratio (Fig. 3A), NMDAR-
mediated EPSC peak amplitude (effect of current: F9,135 = 55.36, P < .01) (Fig. 3B), or
(primarily) AMPAR-mediated spontaneous EPSC amplitude (Fig. 3D) in BLA pyramidal
neurons, suggesting that stress does not alter these aspects of excitatory transmission in the
BLA. However, an increase in excitatory trans-mission was evident in the presence of the
GABAA-R antagonist picrotoxin, as a significant increase in the frequency of spontaneous
EPSCs was observed in stressed mice, as compared to non-stressed controls (Welch-
corrected t-test: t(11) = 2.25, P < .05) (Fig. 3E). Thus, in the absence of inhibitory
modulation, excitatory transmission in the BLA is enhanced following stress.
We next used an internal solution that allowed for simultaneous recording of inhibitory and
excitatory transmission from individual neurons. There was no significant effect of stress on
either glutamatergic spontaneous EPSC amplitude or frequency (Fig. 4A–C) or GABAergic
spontaneous IPSC amplitude or frequency (Fig. 4D–F). Stress had no significant effect on
glutamatergic miniature EPSC amplitude or frequency (Fig. 4F–I), but did significantly
increase GABAergic miniature IPSC amplitude, but not frequency (Fig. 4K– L). Thus, stress
enhanced local inhibitory modulation in the BLA.
ATPA significantly increased GABAergic spontaneous IPSC amplitude, regardless of stress
(ATPA effect: F11,121 =11.63, P <.01, stress effects: ns, ATPA × stress interaction: ns)
(Fig. S1A, B). ATPA also significantly increased GABAergic spontaneous IPSC frequency,
irrespective of stress (ATPA effect: F11,121 = 3.57, P < .01, stress effects: ns, ATPA ×
stress interaction: ns) (Fig. S1A, C). Thus, activation of kainite receptors by ATPA enhances
BLA GABA transmission, an effect which is not modified by stress.
4. Discussion
The results of the current study provide a number of novel insights into the effects of
chronic stress on anxiety-like behavior and associated changes in amygdala glutamatergic
signaling.
Replicating previous findings (Ihne et al., 2012; Mozhui et al., 2010), C57BL/6J mice
chronically exposed to restraint stress showed a significant increase in exploration of the
aversive light compartment in the LDE test. This effect is usually indicative of a decrease in
anxiety-like behavior (Griebel and Holmes, 2013). However, there are also previous
examples in which increased exploration of the aversive areas of anxiety tests, such as the
elevated plus-maze, appear to more related to a drive to escape the apparatus than a low
level of anxiety (Holmes et al., 2000; Nagura et al., 2012). Moreover, C57BL/6J mice
retained certain classic responses to chronic stress, including hypothalamic-pituitary-adrenal
(HPA) axis hyperactivity and a robust loss of body weight (current results and Mozhui et al.,
2010). Thus, as previously argued (Ihne et al., 2012; Mozhui et al., 2010), this behavior may
instead reflect an atypically expressed increased anxiety-like response related to an active-
coping or escape-driven response.
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Regardless of the precise nature of the behavioral response to stress, the current study found
that the stress-induced increase in light compartment exploration was absent following
infusion of the GluK1 kainate receptor agonist, ATPA, directly into the BLA prior to LDE
testing. One possibility is that ATPA exerted an anxiolytic-like effect under non-stressed
conditions that prevented detection of any further increases due to stress. However, infusion
of the drug produced no significant effects in non-stressed mice, suggesting that GluK1
activation may have relieved the effect of stress without affecting anxiety-like behavior
under basal conditions. While further studies would be needed to clarify the stress-
modifying effects of ATPA, GluK1 is an interesting potential target for such modifiers for a
number of reasons.
Previous gene expression analysis found that amygdala GluK1 mRNA expression was
significantly reduced in the BLA of C57BL/6J mice as a result of chronic stress exposure
(Mozhui et al., 2010). Moreover, GluK1 receptors are well positioned to modulate amygdala
responses to stress. The receptor is densely located on the somatodendritic sites of
interneurons in the BLA and bidirectionally regulate GABA release, such that activation of
GluK1 promotes GABA release (Braga et al., 2003; Li et al., 2001). A previous report found
that application of ATPA to BLA-containing brain slices activated GABAergic interneurons
and reduced pyramidal neuron excitability, and also that intra-BLA delivery of the GluK1
antagonist LY3882884 increased anxiety-like behavior (Wu et al., 2007). The GluK1-
mediated increase in GABAergic neurotransmission in the BLA was confirmed in the
current study using slice recordings of spontaneous inhibitory postsynaptic currents in the
presence of ATPA (although there was no indication that this effect was altered by stress,
more detailed analysis would be required to fully exclude such a change). Thus, these
findings raise the possibility that ATPA infusion may work to augment GABAergic
inhibition and attenuate the excitability of glutamatergic BLA neurons to prevent the
behavioral sequelae of stress.
Electrophysiological recordings provided additional insight into the nature of the stress-
related changes in the BLA. Of particular note, while chronic stress exposure did not alter
AMPAR/NMDAR ratio or peak NMDAR-mediated excitatory postsynaptic currents in
pyramidal neurons in the BLA, it did significantly increase the frequency of spontaneous
excitatory postsynaptic currents in the presence of the GABAA-R antagonist picrotoxin. This
demonstrates that stress exposure either led to an increase in glutamate release or an
enhancement of pyramidal neuron network activity in the BLA that was revealed only when
GABAA-R were blocked. The latter seems more likely given there was no indication of a
stress-related increase in spontaneous EPSC amplitude in the presence of the sodium
channel blocker tetrodotoxin, which occludes network activity but leaves glutamate release
intact. Another key finding was a network-independent (i.e. tetrodotoxin-insensitive)
increase in the amplitude of GABAergic miniature inhibitory postsynaptic currents in BLA.
Taken together, this pattern of alterations is consistent with an enhancement of network
excitability of BLA glutamatergic pyramidal neurons, together with a degree of
compensatory upregulation of GABAergic inhibitory transmission. As such, these data add
an important line of physiological evidence to support a model in which stress causes
restricted increases in BLA network hyperexcitability and resultant alterations in anxiety-
like behavior.
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As noted above, activation of GluK1 has been shown to increase GABAergic transmission
in the BLA. In this context, the finding that intra-BLA infusion of ATPA rescued stress-
induced changes in anxiety-like behavior could be explained by a GluK1-mediated increase
in GABAergic activity that effectively opposes the network hyperexcitability caused by
stress. However, there is also evidence that GluK1 activation can increase presynaptic
glutamate release in the rat BLA (Aroniadou-Anderjaska et al., 2012). Furthermore, infusion
of ATPA into the rat BLA has been shown to increase anxiety-like behavior in the LDE test
(Aroniadou-Anderjaska et al., 2012; Lack et al., 2008) – an effect opposite to that found in
the current study and the Wu et al. (2007) study, both using mice. The reason for these
discrepancies is unclear and could reflect genuine species differences in the localization
and/or function of GluK1 in the BLA. Alternatively, some authors have posited that GluK1
may have varying actions on neurotransmission depending on the concentration of
endogenous glutamate in the BLA, with GluK1 effects on GABA predominating under low
concentrations, and effects on glutamate dominating at high concentrations (Braga et al.,
2003). In this scheme, the effects of ATPA in the current study would have worked against a
background of low glutamate. However, this remains speculative in the absence of more
direct evidence and these are clearly important questions that remain to be clarified in future
work.
The role of other glutamatergic signaling molecules in the stress-induced changes in anxiety
behavior we observed also remains to be determined. One potential candidate is GluN1
NMDAR subunit, given prior data indicating an increase in BLA GluN1 mRNA expression
after chronic stress (Mozhui et al., 2010). Intra-BLA infusion of AP5 has also previously
been shown to reverse anxiogenic-like effects produced by GABAA-R blockade (Sajdyk and
Shekhar, 1997). In the current experiments, infusion of the subunit non-specific NMDAR
antagonist AP5 into the BLA of non-stressed mice mimicked the increased light
compartment exploration produced by chronic stress. In contrast to the anxio-selective
changes produced by stress, however, AP5 produced a profile more consistent with
generalized locomotor hyperactivity or behavioral disinhibition – significantly increasing the
total distance as well as the distance traveled in both the (aversive) light and (safe) dark
compartments of the apparatus. Potent disinhibitory/locomotor hyperactivity effects of
systemically administered NMDAR antagonists in mice are well known (e.g., Chen and
Holmes, 2009; Karlsson et al., 2008; Shen and Phillips, 1998), and the current data show
that these drugs can have a similar effect when locally delivered in the BLA. Unfortunately
however, the non-specific behavioral profile produced by AP5 largely prevented meaningful
interpretation of the potential modulatory effect of the drug on stress-induced anxiety-related
behavior. As such, elucidating the potential contribution of GluN1 to stress-induced anxiety-
like behavior will require additional studies.
5. Conclusions
Providing new insight into glutamatergic alterations in the BLA that underlie changes in
anxiety-like behavior due to chronic stress, the current study demonstrated that infusion of
the GluK1 receptor agonist, ATPA, normalized stress-induced anxiety-like behavior. A
similar experiment involving intra-BLA infusion the GluN1 antagonist AP5 was confounded
by profound behavioral disinhibition. Parallel ex vivo physiological analyses of BLA
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synaptic transmission demonstrated a potent GABAergic facilitating effect of ATPA, and
revealed evidence of exaggerated glutamatergic pyramidal neuronal network activity
following chronic stress. Collectively, these data lead to a model of stress-induced BLA
hyperexcitability that is reversed by GluK1-mediated enhancement of GABAergic
neurotransmission to normalize anxiety-like behavior. These findings could have
implications for understanding the pathophysiology of stress-related anxiety disorders and
could suggest novel therapeutic approaches for these disorders that, such GluK1 agonists,
target the glutamate system.
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Fig. 1. Testing effects of intra-BLA infusion of glutamate drugs on stress-induced anxiety-like
behavior
(A) Schematic of experimental design to test for the effects of intra basolateral amygdala
(BLA) infusion of the GluN1 antagonist AP5 or the GluK1 agonist ATPA on behavior in the
light/dark exploration test (LDE) following chronic restraint stress. (B) Coronal sections
indicating site of cannula placements in BLA. (C) Epifluorescent image of a fluorophore
infused into BLA estimating location and spread of infused drugs.
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Fig. 2. Effects of intra-BLA infusion of AP5 or ATPA on stress-induced anxiety-like behavior
(A) Stressed mice showed significantly reduced body weight as compared to non-stressed
controls (con). (B) Stressed mice spent a greater percentage of time in the light compartment
than non-stressed controls following intra-BLA infusion of vehicle, but not after intra-BLA
AP5 or ATPA infusion. Mice infused with AP5 showed spent more time in the light
compartment than vehicle-infused mice, irrespective of stress. (C) Mice infused with AP5
made more entries into the light compartment than vehicle-infused controls, irrespective of
stress. (D) Stressed mice traveled farther overall (inset) as well as in the light compartment
than non-stressed controls following infusion of vehicle, but not after intra-BLA ATPA
infusion. Mice infused with AP5 traveled farther overall and in the light dark compartment
than vehicle-infused controls, an effect which was augmented by stress. Data are means ±
SEM. *P < .05 stress versus non-stressed controls receiving the same treatment, #P < .05
AP5 versus vehicle or ATPA. n = 6–9 per group.
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Fig. 3. Effects of stress on BLA synaptic transmission
(A) Stressed mice showed similar AMPAR/NMDAR ratio as non-stressed controls.
Representative traces show AMPAR/NMDAR ratio in non-stressed controls (con) and
stressed mice (scale bars = 10 pA, 50 ms for ratio). (B) Stressed mice showed similar
electrically-evoked NMDAR EPSC peak amplitude as non-stressed controls. Representative
traces show EPSCs recorded from non-stressed controls and stressed mice (scale bars = 20
pA, 200 ms). (C) Representative traces show spontaneous EPSCs recorded from non-
stressed controls (con) and stressed mice (scale bars = 200 pA, 100 ms). Stressed mice
showed normal spontaneous EPSC amplitude (D) but significantly increased spontaneous
EPSC frequency (E), as compared to non-stressed controls. Data are means ± SEM. *P < .
05 stress versus non-stressed controls. n = 8–9 per group.
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Fig. 4. Effects of stress on BLA spontaneous and miniature synaptic transmission
(A) Representative traces for spontaneous EPSCs. Stressed mice showed a similar amplitude
(B) and frequency (C) of spontaneous EPSCs, as compared to non-stressed controls (con).
(D) Representative traces for spontaneous IPSCs. The amplitude (E) and frequency (F) of
spontaneous IPSCs was similar between stressed and non-stressed mice. (G) Representative
traces for miniature EPSCs. Stressed mice showed a similar amplitude (H) and frequency (I)
of miniature EPSCs, relative to non-stressed controls. (J) Representative traces for miniature
IPSCs. Stressed mice showed increased miniature IPSC amplitude (K), but not frequency
(L), relative to non-stressed controls. Data are means ± SEM. *P < .05 stress versus non-
stressed controls. n = 6–7 per group.
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